Bavarian Nordic (BAVA.CO) Stock Analysis & AI Equity Report
Bavarian Nordic (BAVA.CO) overview
Bavarian Nordic (BAVA.CO) stock analysis and AI equity research. For the latest completed financial year, 2024, Bavarian Nordic reported revenue of DKK 5,716m and operating profit of DKK 940m; the year-end share price was 189.35 DKK and market capitalisation was DKK 14,789m. Bavarian Nordic is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Bavarian Nordic's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-18. Data will be refreshed during report generation.
About Bavarian Nordic
Bavarian Nordic is a vaccines company focused on researching, developing, manufacturing, and commercializing preventive vaccines. Its portfolio includes travel vaccines such as rabies, tick-borne encephalitis, cholera, typhoid, and chikungunya vaccines, as well as smallpox and mpox vaccines supplied to governments and international organizations for public health preparedness.
Generate the Bavarian Nordic report
Bavarian Nordic is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Bavarian Nordic and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.